The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Tue, 08th Feb 2022 13:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Tuesday and not separately reported by Alliance News:

----------

Round Hill Music Royalty Fund Ltd - New York-based music copyright investment company - Acquires significant majority of the music rights for American rock band Alice In Chains. Does not disclose financial details for deal. The acquisition covers the publishing, masters and neighbouring rights of the band, including a catalogue comprising 94 compositions and 159 recordings. "Revenue from the catalogue is attributable to a diverse group of sources...In terms of geographical exposure, 75% of the revenue is from the US, while the remaining balance is from other countries," Round Hill says.

----------

Aquis Exchange PLC - London-based stock exchange operator and software developer - Partners with Investre, which is building an exchange for retail customers to buy and sell "values-driven" investment funds - either direct from the asset manager on the primary market, or by trading with other users through an auction process on the secondary market. "Aquis is providing the technology to power the secondary market, by supplying a fully outsourced technology model to Investre consisting of its award-winning Aquis Matching Engine, its Aquis Market Surveillance product, as well as ongoing operational support to the business. The duration of the contract will be three years, and the value of the contact will not be disclosed," company says.

----------

Beeks Financial Cloud Group PLC - Glasgow-based provider of connectivity for financial markets - Signs GBP2.5 million contract extension over three years with an existing unnamed tier 1 customer. The contract is for the provision of private cloud services into an additional geography, Beeks notes. Chief Executive Gordon McArthur says: "We continue to secure notable contracts with some of the world's largest players in the financial services industry, demonstrating our growing reputation and the quality of our offerings. This latest contract contributes towards underpinning our financial 2023 expectations. With growing levels of committed future revenues and a record pipeline, we are confident in continued growth."

----------

Cap-XX Ltd - New South Wales, Australia-headquartered manufacturer of ultra-thin prismatic and cylindrical supercapacitors - Wins contract from MCCI Corp, an open-source developer for LoRaWAN long-range wireless IoT networks. MCCI selects ultra-thin CAP-XX HW103 1Farad 2.75V supercap for its Model 4906 Supercap FeatherWing LoRa Module. "MCCI chose the CAP-XX supercapacitor for its thin form factor that fits easily in the Adafruit-Feather-compatible footprint, and for its low Equivalent Series Resistance which enables the high bursts of power needed for LoRa wireless data transmissions in both consumer Internet of Things and industrial IoT devices such as remote monitoring sensors," company says. Chief Executive Anthony Kongats says the deal proves how company's prismatic supercapacitors can be "excellent supporting actors" for power management in space-constrained IoT devices.

----------

LBG Media PLC - Manchester-based digital media and youth content publisher, also known as LADbible - Expects 2021 revenue to be at least GBP54 million, slightly ahead of expectations and increasing by 80% from GBP30.2 million in 2020. Adjusted earnings before interest, tax, depreciation, and amortization will be slightly ahead of market consensus of GBP16.2 million. Says direct revenue growth was driven by a significant increase in content marketing and direct display sales in the UK, Australia and Ireland. Notes indirect revenue increased significantly, primarily due to a 97% increase in views of group-generated content. Chief Executive Solly Solomou says 2021 performance "outstanding, both financially and operationally".

----------

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - After signing exclusive global licensing agreement with Oxilio Ltd for NXP001 in September, Oxilio progresses product and signs "significant" service contract with Quotient Sciences Ltd to support the formulation development of NXP001. This is a proprietary new form of aprepitant which is currently marketed for cancer chemotherapy induced nausea and vomiting. "Under the contract Oxilio will work with Quotient Sciences, a drug development and manufacturing accelerator, to identify and evaluate the cocrystal formulation of aprepitant to deliver optimal bioavailability for the treatment of CINV," Nuformix explains.

----------

Armadale Capital PLC - investment company focussed on mining projects in Africa - Makes further progress developing the mining lease at the Mahenge Liandu project in Tanzania, as part of its plans to commission commercial operations. Applies for three incremental exploration licences, which it hopes will "materially enhance" the Mahenge Liandu project's exploration potential.

----------

Riverstone Energy Ltd - Guernsey-based investor in energy companies and assets - Will sell its entire stake in Pipestone Energy Corp for CAD53.0 million, about GBP30.8 million. Riverstone says it will use the proceeds as part of its plan to recommence its share buyback programme. Riverstone said it decided to allocate an additional GBP46 million to the GBP40 million programme launched last May. It already has repurchased 7.7 million shares at a total cost of GBP36 million.

----------

Eco Atlantic Oil & Gas Ltd - oil and gas exploration company focused on Guyana and Namibia - Signs definitive share purchase agreement to buy 100% of Azinam Group Ltd in return for a 16.5% equity stake in the company. Co-Founder & Chief Executive Gil Holzman says: "This now puts the company a step further towards joining all of Azinam's offshore exploration acreage into our broader portfolio. We are working towards drilling a well on Block 2B, a highly prospective play in the Orange Basin, offshore South Africa, close to the recent discovery by Shell PLC and Qatar Energy in the Orange Basin in Namibia. The well is planned for the second half of this year." Azinam owns a portfolio of offshore petroleum assets in Namibia and South Africa.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

Wednesday 13 March 
abrdn China Investment Co LtdGM re liquidation
Safestore Holdings PLCAGM
Wincanton PLCGM re takeover by CEVA Logistics
Thursday 14 March 
Angus Energy PLCGM
Bank of Georgia Group PLCGM re acquisition of Ameriabank CJSC
Blackrock Sustainable American Income Trust PLCAGM
Friday 15 March 
BlackRock Energy & Resources Income Trust PLCAGM
Chrysalis Investments LtdAGM
Quantum Exponential Group PLCGM re delisting from AQSE
TruSpine Technologies PLCAGM (adjourned 2022)
United Oil & Gas PLCGM re fundraise and share sub-division
Monday 18 March 
MGC Pharmaceuticals LtdGM re change of company name to Argent Biopharma
Schroder European Real Estate Investment Trust PLCAGM
Tuesday 19 March 
BlackRock Throgmorton Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Eco Animal Health Group PLCGM re share buybacks
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Nuformix PLCAGM
Scirocco Energy PLCGM re requisitioned resolution to implement cash strategy
Various Eateries PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis.

Read more
18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year.

Read more
17 Aug 2023 15:43

UK shareholder meetings calendar - next 7 days

Friday 18 August 
Adams PLCAGM
ME Group International PLCGM re proposed share buyback
Oxford BioDynamics PLCGM re placing
Pathfinder Minerals PLCGM re disposal of the subsidiary
Monday 21 August 
Calculus VCT PLCAGM
Home REIT PLCGM re changes to the investment policy
Tuesday 22 August 
Cake Box Holdings PLCAGM
ReNeuron Group PLCAGM
RUA Life Sciences PLCAGM
Smoove PLCAGM
STM Group PLCAGM
Wednesday 23 August 
Brandshield Systems PLCAGM
James Latham PLCAGM
LifeSafe Holdings PLCGM re shareholder circular
Momentum Multi-Asset Value Trust PLCGM re appointment of the liquidators
Sovereign Metals LtdGM re share placement options
Thor Energy PLCGM re proposed share consolidation
Thursday 24 August 
Ananda Developments PLCAGM
Concurrent Technologies PLCAGM
CyanConnode Holdings PLCAGM
Nuformix PLCAGM
Oryx International Growth Fund LtdAGM
ThomasLloyd Energy Impact Trust PLCAGM
ThomasLloyd Energy Impact Trust PLCGM re market purchases of its own ordinary shares
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 May 2023 12:45

Nuformix loss narrows; near-term goal to focus on NXP002 asset

(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Apr 2023 12:14

Nuformix raises GBP70,000 to fund NXP002 programme

(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Feb 2023 12:12

Nuformix progresses NXP002 trial after acquiring human tissue

(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Read more
13 Dec 2022 14:54

Nuformix interim loss virtually flat as continues work on drugs

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.

Read more
23 Sep 2022 21:02

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Aug 2022 16:01

UK shareholder meetings calendar - next 7 days

Friday 19 August 
Braemar Shipping Services PLCAGM
Citius Resources PLCAGM
Next Fifteen Communications Group PLCGM re acquisition of M&C Saatchi
Volex PLCAGM
Monday 22 August 
African Pioneer PLCAGM
Argentex Group PLCAGM
Nostrum Oil & Gas PLCGM operational update
Ondo InsurTech PLCAGM
Sabien Technology Group PLCGM re broker option
Scottish Investment Trust PLCGM re recombination of assets with JPMorgan Global Growth & Income plc
Trackwise Designs PLCAGM
Tuesday 23 August 
Bezant Resources PLCAGM
Livermore Investments Group LtdAGM
Xtract Resources PLCAGM
Wednesday 24 August 
Amur Minerals CorpGM subsidiary sale
Creightons PLCAGM
Goldstone Resources LtdAGM
Thursday 25 August 
Ince Group PLCGM fundraising
McBride PLCGM increase in borrowing limit
NatWest Group PLCGM re approval of special dividend
Nuformix PLCAGM
Triple Point Energy Efficiency Infrastructure Co PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Aug 2022 11:14

IN BRIEF: Nuformix shares rise on tolerability studies completion

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.